Psychiatry

This month in review highlights MDMA-assisted therapy coverage, experiences with zuranolone a year after its approval, and early positive data on potential treatments.

A phase 2 trial met its primary endpoint, showing NBI-1117568, the first M4 selective agonist, is effective and safe at treating adult schizophrenia.

Michigan Medicine and U-M research finds a bidirectional link between mental health disorders and chronic diabetes complications, urging comprehensive screenings.

A new study significantly demonstrated semaglutide, but not liraglutide, is associated with suicidal ideation.

A new study found unvaccinated people have a greater risk of depression or serious mental health illnesses compared to vaccinated people.

Uric acid levels, commonly used to indicate gout, are closely associated with bipolar-affected mania.

Preliminary Phase 1b data demonstrated the favorable safety and tolerability profile of VLS-01 buccal film, with psychedelic effects resolved by 120 minutes.

Cristina Pearse, an MDMA-assisted therapy trial participant, expresses disappointment in the FDA’s decision not to approve MDMA-assisted therapy.

The US FDA has issued a CRL and requested an additional phase 3 trial for MDMA-assisted therapy in the management of PTSD.

A new study revealed an increased risk of psychiatric and autoimmune comorbidities after an alopecia areata diagnosis.

A new study found approximately 40% with osteoarthritis and 36.3% with RA screened positive for anxiety, depression, and fibromyalgia.

A study suggests TMR can boost PTSD treatment by enhancing memory consolidation during sleep, showing significant symptom reduction without affecting sleep quality.

PTSD experts explore unmet PTSD needs, the potential of psychedelic therapies, and key unanswered questions about MDMA-assisted therapy for PTSD.

A recent study found a high prevalence of head injuries among law enforcement officers may make them more prone to experiencing mental health issues.

In an interview with HCPLive, Angela Moreland, PhD, highlighted the largest takeaway from the study on the psychiatric impact of mass shootings on the greater community.

In a "secret shopper" study, investigators posing as Medicaid enrollees found many clinicians in Medicaid provider directories do not accept Medicaid insurance.

A year after zuranolone’s FDA approval for postpartum depression on August 3, 2023, prescribers and a patient weigh in about the medication’s success in alleviating symptoms.

Investigators found patients with comorbid temporomandibular disorder, migraines, and fibromyalgia experienced longer pain duration than patients with only 1 comorbidity.

This month in review captures the top news in the psychiatry field during July.

This extended-release injectable suspension for schizophrenia and schizoaffective disorder is approved as a monotherapy and as an adjunct to mood stabilizers or antidepressants.

A new study found using e-cigarettes with partial nicotine reduction was linked to greater puffing time, puff duration, and total inhaled volume than 5% nicotine concentration.

A new study found the group with the shortest seizure duration of ≤ 20 seconds had the lowest remission rate of 27.2%, compared with a 39.3% overall remission rate.

Depression A new study discovers a dual pathway framework where antidepressants are concomitantly negatively and positively linked to alcohol use.

A study found wearable devices alerting irregular heart rhythms amplified anxiety in 1 in 5 participants with atrial fibrillation, which led people to be more likely to seek care.

A new study found claims for services of opioid treatment programs rose among Medicare beneficiaries after Medicare started covering them.

A new study found probable PTSD was prevalent among adults in the community after a mass shooting, with greater prevalence among those previously assaulted.

In this part of our 5-part series, Gus Alva, MD talks about MDMA's efficacy in controlled settings and addresses misconceptions.

In this part of our 5-part series, Gus Alva, MD discusses the unmet need in PTSD treatment and the potential of MDMA-assisted therapy.

A study demonstrated a smartphone app provides comparable benefits to cognitive behavior or mindfulness-based therapy, widening the supply gap for mental health care.

A study found the association between physical activity engagement and reduction in depression symptoms is moderated by pain.